Company
Nocion Therapeutics
Amplifying possibilities with a new class of treatment for chronic cough and other diseases of sensory neuron hypersensitivity
Also known as Nocion Therapeutics, Inc.
- Status
- Operatingas of 2026-09-17
- Headquarters
- Needham, MA, United States
- Legal name
- Nocion Therapeutics, Inc.
- nociontx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 17 September 2026
About
Our mission is to bring long-awaited relief to people with chronic cough and other diseases of sensory neuron hypersensitivity with a new class of charged sodium channel blockers
Funding snapshot
- Total raised
- $155MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series B, $93M2026-01-07
Funding rounds
- Series B
- $93M2026-01-07, Company stated
- Round, 2025
- $23M2025-12-15, SEC form D sold, 13 investors
- Series B
- $62M2024-03-04, Company stated
- Round, 2024
- $31.1M2024-02-29, SEC form D sold, 13 investors
- Round, 2021
- $7M2021-08-18, SEC form D sold, 10 investors
- Round, 2021
- $15M2021-01-05, SEC form D sold, 11 investors
Products
- Other
- taplucainium
Loading relationship preview